Boston Scientific (BSX) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Boston Scientific (BSX) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 17.54% |
| 10 | Zimmer Biomet Holdings | 19.36 Bn | 18.95 Bn | 1.54 Bn | -1.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.47% |
| Mar 31, 2026 | 64.73% |
| Dec 31, 2025 | 74.72% |
| Sep 30, 2025 | 63.10% |
| Jun 30, 2025 | 47.97% |
| Mar 31, 2025 | 90.82% |
| Dec 31, 2024 | 91.86% |
| Sep 30, 2024 | 5.01% |
| Jun 30, 2024 | 23.50% |
| Mar 31, 2024 | 14.82% |
| Dec 31, 2023 | 37.09% |
| Sep 30, 2023 | 70.86% |
| Jun 30, 2023 | 54.75% |
| Mar 31, 2023 | 201.01% |
| Dec 31, 2022 | -68.41% |
| Sep 30, 2022 | 11.36% |
| Jun 30, 2022 | 16.90% |
| Mar 31, 2022 | -38.84% |
| Dec 31, 2021 | -40.82% |
| Sep 30, 2021 | -2.13% |